Have a feature idea you'd love to see implemented? Let us know!

AIM AIM ImmunoTech Inc

Price (delayed)

$0.2051

Market cap

$13.07M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.47

Enterprise value

$15.55M

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease ...

Highlights
The company's EPS rose by 18% QoQ but it fell by 9% YoY
The net income has decreased by 15% YoY but it has increased by 15% from the previous quarter
AIM ImmunoTech's equity has shrunk by 87% YoY and by 52% QoQ
AIM ImmunoTech's quick ratio has plunged by 85% YoY and by 38% from the previous quarter

Key stats

What are the main financial stats of AIM
Market
Shares outstanding
63.71M
Market cap
$13.07M
Enterprise value
$15.55M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.02
Price to sales (P/S)
62.26
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
81.85
Earnings
Revenue
$190,000
EBIT
-$23.48M
EBITDA
-$23.1M
Free cash flow
-$20.65M
Per share
EPS
-$0.47
Free cash flow per share
-$0.36
Book value per share
$0.05
Revenue per share
$0
TBVPS
$0.19
Balance sheet
Total assets
$13.59M
Total liabilities
$10.68M
Debt
$3.4M
Equity
$2.91M
Working capital
-$2.53M
Liquidity
Debt to equity
1.17
Current ratio
0.75
Quick ratio
0.71
Net debt/EBITDA
-0.11
Margins
EBITDA margin
-12,157.9%
Gross margin
81.1%
Net margin
-12,594.2%
Operating margin
-14,694.2%
Efficiency
Return on assets
-147.5%
Return on equity
-397.6%
Return on invested capital
-610.6%
Return on capital employed
-673.1%
Return on sales
-12,355.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AIM stock price

How has the AIM ImmunoTech stock price performed over time
Intraday
-0.92%
1 week
-10.04%
1 month
-17.96%
1 year
-56.65%
YTD
-53.38%
QTD
-24.04%

Financial performance

How have AIM ImmunoTech's revenue and profit performed over time
Revenue
$190,000
Gross profit
$154,000
Operating income
-$27.92M
Net income
-$23.93M
Gross margin
81.1%
Net margin
-12,594.2%
The company's operating margin fell by 21% YoY but it rose by 6% QoQ
The operating income has contracted by 19% YoY but it has grown by 12% from the previous quarter
The net margin has declined by 17% year-on-year but it rose by 10% since the previous quarter
The net income has decreased by 15% YoY but it has increased by 15% from the previous quarter

Growth

What is AIM ImmunoTech's growth rate over time

Valuation

What is AIM ImmunoTech stock price valuation
P/E
N/A
P/B
4.02
P/S
62.26
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
81.85
The company's EPS rose by 18% QoQ but it fell by 9% YoY
The P/B is 151% higher than the 5-year quarterly average of 1.6 and 6% higher than the last 4 quarters average of 3.8
AIM ImmunoTech's equity has shrunk by 87% YoY and by 52% QoQ
AIM's P/S is 79% below its 5-year quarterly average of 292.9 and 39% below its last 4 quarters average of 101.6
AIM ImmunoTech's revenue has decreased by 5% QoQ

Efficiency

How efficient is AIM ImmunoTech business performance
The return on invested capital has dropped by 172% year-on-year
AIM's ROA has shrunk by 147% YoY and by 4.1% QoQ
The ROE has plunged by 55% from the previous quarter
The company's return on sales fell by 15% YoY but it rose by 11% QoQ

Dividends

What is AIM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AIM.

Financial health

How did AIM ImmunoTech financials performed over time
The total assets is 27% greater than the total liabilities
The company's total liabilities has surged by 103% YoY and by 11% QoQ
AIM ImmunoTech's quick ratio has plunged by 85% YoY and by 38% from the previous quarter
The debt is 17% greater than the equity
AIM's debt to equity has surged by 113% since the previous quarter
AIM ImmunoTech's equity has shrunk by 87% YoY and by 52% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.